Sunshine Biopharma, Inc. (SBFM)
2.46
-0.11 (4.28%)
Upcoming Events
Latest Headlines
Sunshine Biopharma Announces Canadian Approval for Rivaroxaban, a Generic Form of Xarelto(R)
June 1, 2026 8:00 AM - StreetInsider
Form PRE 14C Sunshine Biopharma Inc. For: May 29
May 29, 2026 4:07 PM - SEC Filing
Form 8-K Sunshine Biopharma Inc. For: May 28
May 29, 2026 4:07 PM - SEC Filing
Sunshine Biopharma receives patent for coronavirus treatment compounds
May 29, 2026 8:01 AM - StreetInsider
Sunshine Biopharma Announces Issuance of U.S. Patent 12,624,066 B2 Covering Novel Coronavirus Treatment Technology
May 29, 2026 8:00 AM - StreetInsider
Sunshine Biopharma executes reverse stock split to meet NASDAQ requirements
May 28, 2026 9:00 AM - StreetInsider
Sunshine Biopharma Announces Reverse Stock Split to Maintain NASDAQ Listing
May 28, 2026 9:00 AM - StreetInsider
Form SCHEDULE 13G Sunshine Biopharma Inc. Filed by: L1 Capital Global Opportunities Master Fund, Ltd.
May 22, 2026 4:10 PM - SEC Filing
Form SCHEDULE 13G Sunshine Biopharma Inc. Filed by: BIGGER CAPITAL FUND L P
May 21, 2026 4:17 PM - SEC Filing
Sunshine Biopharma Receives Canadian Regulatory Approval for Generic Amoxicillin
May 21, 2026 7:00 AM - StreetInsider
Form 8-K Sunshine Biopharma Inc. For: May 18
May 19, 2026 4:06 PM - SEC Filing
Sunshine Biopharma closes $6 million public offering with warrant potential
May 19, 2026 12:09 PM - StreetInsider
Sunshine Biopharma Inc. Announces Closing of up to $18.0 Million Public Offering
May 19, 2026 12:09 PM - StreetInsider
Form 424B4 Sunshine Biopharma Inc.
May 19, 2026 11:03 AM - SEC Filing
Form EFFECT Sunshine Biopharma Inc.
May 19, 2026 6:05 AM - SEC Filing
Sunshine Biopharma prices $6 million public offering at $0.50 per unit
May 18, 2026 12:18 PM - StreetInsider
Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering
May 18, 2026 12:18 PM - StreetInsider
Form 10-Q Sunshine Biopharma Inc. For: Mar 31
May 13, 2026 4:20 PM - SEC Filing
Form S-1 Sunshine Biopharma Inc.
May 12, 2026 4:17 PM - SEC Filing
Form 4 Sunshine Biopharma Inc. For: Apr 14 Filed by: NATAN DAVID
April 14, 2026 4:26 PM - SEC Filing
Form 8-K Sunshine Biopharma Inc. For: Apr 06
April 9, 2026 4:05 PM - SEC Filing
Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year
April 6, 2026 8:30 AM - StreetInsider
Form 10-K Sunshine Biopharma Inc. For: Dec 31
April 3, 2026 11:59 AM - SEC Filing
Form NT 10-K Sunshine Biopharma Inc. For: Dec 31
March 31, 2026 4:05 PM - SEC Filing
Form 8-K Sunshine Biopharma Inc. For: Mar 06
March 9, 2026 4:06 PM - SEC Filing
Full Article List
